Authors' Reply to Huang and Zhang: Comment on "Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study"
Drugs
; 83(5):465-467, 2023.
Article
in English
| EMBASE | ID: covidwho-2304846
cardiovascular disease; cardiovascular risk; cause of death; chronic kidney failure; clinical classification; clinical decision making; confounding variable; coronavirus disease 2019; data base; delirium; dementia; disease association; disease severity; drug dependence; drug efficacy; drug safety; erectile dysfunction; follow up; Food and Drug Administration; gout/dt [Drug Therapy]; human; hyperuricemia; icd-10; incidence; International Classification of Diseases; International Index of Erectile Function; letter; lung alveolus hypoventilation; major depression; male; medical information; mitral valve prolapse; mood disorder; morbid obesity; motor dysfunction; outcome assessment; patient selection; propensity score; prospective study; psychosis; public health; sample size; side effect; sleep deprivation; sleep disorder; symptom; allopurinol/dt [Drug Therapy]; febuxostat/dt [Drug Therapy]; phosphodiesterase V inhibitor; urate/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
Drugs
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS